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Introduction: AT-101 is an oral, pan Bcl-2 family protein inhibitor
that has demonstrated activity in small cell lung cancer (SCLC)
models. A phase I/II study was conducted combining AT-101 with
topotecan in relapsed and refractory SCLC.
Methods: An open-labeled multicenter phase I/II study was conducted
of oral AT-101 with intravenous topotecan in patients with SCLC who
had progressed on prior platinum-containing chemotherapy. The phase
II portion was a two-stage design, and two cohorts of patients, sensitive
relapsed and refractory, were analyzed. Primary endpoint in the two-
stage phase II portion was response rate; secondary endpoints were
duration of response and time to progression.
Results: Thirty-six patients were enrolled. The most common toxicities
were hematologic, as would be expected with topotecan and AT-101.
The recommended phase II dose was 40 mg AT-101 days 1 to 5 with
topotecan 1.25 mg/m2 days 1 to 5 on a 21-day cycle. In the sensitive-
relapsed cohort (n  18), there were 0 complete response (CR), three
partial response (PR), 10 stable disease (SD), and four progressive
disease (PD). In the refractory cohort (n  12), there were 0 CR/PR,
five SD, and five PD. The study did not meet its prespecified endpoints
to continue enrollment in the second stage of the phase II study. Median
time to progression in the sensitive-relapsed cohort was 17.4 weeks and
11.7 weeks in the refractory cohort.
Conclusions: AT-101 can be safely combined with topotecan at a
reduced dose of 1.25 mg/m2. The response rates observed did not
meet the criteria for additional enrollment; however, many patients
had a best response of SD and the median time to progression in
both cohorts was favorable. Additional trials of AT-101 in SCLC are
ongoing.
Key Words: Small cell lung cancer, BCL-2 inhibitor,
Chemotherapy.
(J Thorac Oncol. 2010;5: 1637–1643)
Lung cancer is the leading cancer-related killer of both menand women in the United States.1 Small cell lung cancer
(SCLC) comprises approximately 13% of all lung cancers in the
United States2; this translates to approximately 30,000 patients
diagnosed with SCLC in 2009. Despite very high initial re-
sponse rates to treatment, median survival for limited SCLC is
only 20 months and for extensive SCLC, 10 to 12 months.3,4
The majority of patients with SCLC present with ex-
tensive disease, and initial first-line therapy for extensive
SCLC is typically platinum and etoposide chemotherapy.5
Although response rates to first-line chemotherapy are high,
disease usually recurs, and 5-year survival is under 5%.6
Patients are considered to have sensitive relapse when disease
recurs beyond 60 to 90 days after completion of first-line
chemotherapy and refractory disease when recurrence occurs
earlier. Response rates to topotecan, a topoisomerase-I inhib-
itor approved for use in chemotherapy-sensitive relapsed
disease, is approximately 24% in sensitive relapsed7 and
11% in refractory8,9 disease. Clearly, there is room for
improvement in the treatment of patients with SCLC.
Bcl-2 is overexpressed in up to 90% of SCLC. AT-101
[R-(-)-gossypol acetic acid; Ascenta Therapeutics, Inc.] is a
polyphenolic compound that inhibits the function of Bcl-2,
Bcl-xL, and Mcl-1 by acting as a BH3 mimetic. AT-101 binds to
Bcl-2 and Bcl-xL in the BH3 binding pocket of these proteins
and lowers the threshold for cancer cells to undergo apoptosis.10
More recent studies have also indicated that AT-101 treatment
results in potent induction of the natural ligands of Mcl-1, Bcl-2,
and Bcl-xL, Noxa and Puma, which are proapoptotic,11 as well
as inhibiting angiogenesis.12,13 Preclinical studies in SCLC using
cell lines and mouse models have shown both single-agent
antitumor activity of AT-101 and potent synergy when com-
bined with chemotherapies such as topotecan.14 These studies
suggested AT-101 activity in Bcl-2 and Mcl-1 expressing SCLC
models. Given the strong molecular rationale and preclinical
data showing synergy, a phase I/II trial evaluating safety and
efficacy of AT-101 with topotecan in relapsed and refractory
SCLC was initiated.
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PATIENTS AND METHODS
Patient Selection
This study was approved by the institutional review
board of all participating institutions. Patients who were 18
years and older with histologically or cytologically confirmed
SCLC were eligible for the study. Patients with limited or
extensive stage disease at the time of diagnosis were eligible.
All patients had to have progression of disease after only one
prior platinum-containing chemotherapy regimen; prior iri-
notecan was not allowed. Other eligibility criteria included:
PS 0 to 1, measurable disease, no unstable or progressive
brain metastases, ability to swallow oral medications, and no
other active malignancy. Patients were required to have
adequate hematologic function (absolute neutrophil count
1.5  109/liter, Hgb 9 g/dl, platelet 100  109/liter),
and adequate liver and renal function (serum creatinine 1.5
mg/dl or creatinine clearance 60 ml/min, total bilirubin
1.5 mg/dl, and aspartate aminotransferase and alanine ami-
notransferase 2.5  upper limit of normal).
Study Design
This was an open-labeled multicenter phase I/II study with
a two-stage design to evaluate the safety and efficacy of oral
AT-101 administered in combination with topotecan in patients
with SCLC who had progressed on prior platinum-containing
chemotherapy. The phase I portion of this study was designed to
enroll cohorts of patients to assess the tolerability and safety of
the combination of topotecan and AT-101 and determine the
recommended phase II dose for the combination. At the recom-
mended phase II dose, an additional 100 patients were planned
to be treated to assess response rate, with patients with relapsed
and refractory SCLC being analyzed separately, using a two-
stage design. Secondary endpoints were duration of response
and time to disease progression.
During the phase I portion of the study, the starting dose
of topotecan was 1.25 mg/m2 intravenous over 30 minutes, daily
for 5 consecutive days, repeated every 21 days, and the planned
dose levels of AT-101 began at 40 mg daily on days 1 to 5 of
each cycle with topotecan. Because other concurrently con-
ducted studies showed that total doses of AT-101 of 60 mg/d
were associated with dose-limiting elevation in liver enzymes,
the dose of AT-101 was not increased further.15 Therefore, if 40
mg was tolerated, it was planned to be the maximum tolerated
dose of AT-101 in combination with topotecan 1.25 mg/m2. One
dose deescalation of AT-101 to 30 mg/d was allowed, based on
AT-101 tolerability. Dose-limiting toxicities were defined as
adverse events considered by the investigator to be possibly
related to or related to AT-101 and for the purposes of the phase
I portion were those that occurred in the first cycle of treatment.
Dose limiting toxicities (DLTs) were defined as grade 3
nonhematologic toxicity; grade 3 nausea, vomiting, or diar-
rhea uncontrolled by maximal antiemetic/diarrheal therapy; el-
evated serum troponin (of institutional range); ileus or small
bowel obstruction of any grade; grade 4 neutropenia or throm-
bocytopenia lasting 7 days; grade 4 neutropenia and fever
38.5°C; grade 3 neutropenia with grade 3 infection; and
thrombocytopenia of any grade if associated with clinically
significant bleeding. The serum troponin was added as a DLT as
damage to heart muscle had been seen in animal studies. This
was not seen in human studies, although one person in a prior
study had had a heart attack while receiving AT-101, although
he had a history of heart attacks and the treating physician had
thought this was unrelated to study drug. Given the high inci-
dence of certain toxicities known to be associated with topotecan
(e.g., grade 4 neutropenia), a provision in the protocol mandated
that at each dose level, the medical monitor and principal
investigators of the study would confer on the data and deter-
mine further dose modifications.
Once the recommended phase II dose was determined,
all patients in phase II of the study were to be treated with this
dose. Patients continued treatment until disease progression
or unacceptable toxicity.
Baseline and Treatment Assessments
At study entry, all patients underwent a complete his-
tory and physical, including complete blood count, serum
chemistries, and electrocardiogram. Imaging studies includ-
ing computed tomography of the chest and abdomen and
computed tomography or magnetic resonance imaging of the
brain were required within 2 weeks before start of treatment.
Subsequent imaging studies were performed every two cycles
and at the end of the treatment. Assessment of tumor response
was based on RECIST criteria. Adverse events were captured
using the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 3.0 (NCI CTCAE v3).
Doses were allowed to be delayed for up to 2 weeks for
resolution of toxicity, and two dose modifications during the
phase II portion of the study were allowed.
Statistical Analysis
The phase II portion of the study accrued patients in
two parallel cohorts. Cohort A included patients with chemo-
therapy-sensitive relapsed disease, defined as disease pro-
gression that occurs 60 days from completion of the first-
line chemotherapy regimen. Cohort B included patients with
refractory disease, defined as disease that progresses during
or 60 days from the completion of initial therapy. As
sensitive-relapsed and refractory patients are expected to
have different responses to second-line treatment, the two
cohorts were analyzed separately. A Simon optimal two-stage
experimental design was used within each cohort with type I
(alpha) error of 0.05 and type II (beta) error of 0.20, with
early stopping rules if the responses did not meet criteria to
move forward. The exact binomial type I (alpha) error of
0.0405 and a type II (beta) error of 0.15 (85% power) was
used in the final sample size calculation. For cohort A
(chemotherapy sensitive), the study was designed to test a
null hypothesis of a tumor response rate of no more than
25%, versus a response rate of interest of 45%. A total of 17
patients were planned to be accrued in stage 1 and 38 patients
in stage 2. At least six responses had to be observed in the
first stage to continue accrual into the second stage. At least
20 responses had to be observed in both stages to warrant
further investigation in future studies. For cohort B (refrac-
tory), the study was designed to test a null hypothesis of a
tumor response of no more than 5%, versus a response rate of
interest of 20%. A total of 10 patients were planned to be
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accrued in stage 1 and 35 patients in stage 2. At least 1
response had to be observed in the first stage to continue
accrual to stage 2. At least six responses had to be observed
in both stages to warrant further investigation in future
studies.
RESULTS
Patient Characteristics
From February 5, 2007, to March 11, 2008, a total of 36
patients were enrolled at 17 different sites. See Table 1 for
patient characteristics.
Phase I, Dose-Finding Safety Cohort
The phase I portion of the study started with topotecan
1.25 mg/ m2 on days 1 to 5 and AT-101 40 mg on days 1 to
5 of a 21-day cycle. Eleven patients were treated in the phase
I portion of the study; five at 40 mg of AT-101 and six at 30
mg of AT-101. The dose-limiting toxicity in the 40 mg cohort
was grade 4 ANC lasting7 days in two patients. There were
no DLTs in the 30 mg cohort, but grade 4 neutropenia lasting
7 days occurred in two patients and grade 4 thrombocyto-
penia lasting 7 days occurred in one patient. On review of
the toxicities with the entire investigator group, it was be-
lieved that the DLTs and cytopenias observed were consistent
with what might be expected with treatment with topotecan
alone, and there seemed to be little difference in the rate of
grade 4 cytopenias between the two doses of AT-101 tested.
Dose-limiting nonhematologic toxicities were not observed at
either dose level. Therefore, the recommended phase II dose
of AT-101 was 40 mg in combination with topotecan 1.25
mg/m2 on days 1 to 5. Use of myeloid growth factors had not
been allowed in the first cycle of chemotherapy in the phase
I portion of the trial, but with the recommended phase II
dosing, use of myeloid growth factors was recommended.
Toxicities
Adverse events that were reported in at least 10% of the
patients enrolled in this study are shown in Table 2. The most
common toxicities were hematologic, as would be expected
in this SCLC population treated with a combination of topo-
tecan and AT-101. Gastrointestinal side effects were also
common, although most of these were grades 1 and 2.
Response Rate
A total of 30 patients were enrolled at the recom-
mended phase II dose of 40 mg of AT-101 with topotecan
1.25 mg/m2. All patients treated at the recommended phase II
dose were analyzed for response, whether they had enrolled
in the phase I or II portion of the study. In cohort A (sensitive
relapsed), there were 18 patients enrolled at this dose level
and in cohort B (refractory), 12 patients enrolled.
In the sensitive-relapsed cohort, there were 0 complete
response (CR), three partial response (PR), 10 stable disease
(SD), and four progressive disease (PD). One patient was not
evaluable for response. In the refractory cohort, there were 0
CR or PR, five SD, five PD, and two patients who were not
evaluable for response. Figure 1 shows a waterfall plot of the
best response in all 36 patients on study, and Figures 2 and 3
show waterfall plots for the subsets of sensitive-relapsed and
refractory patients.
Median time to progression in the sensitive-relapsed
cohort was 17.4 weeks and 11.7 weeks in the refractory
cohort. Of note, two patients who had PR in the sensitive-
TABLE 1. Patient Characteristics
Patient Characteristics
Phase I Phases I and II, 40 mg
All
AT-101
30 mg
AT-101
40 mg
Cohort A,
n (%)
Cohort B,
n (%)
Median age (range) 72 (52–76) 54 (50–67) 56 (41–72) 59 (47–75) 58 (41–76)
Male 5 (83%) 1 (20%) 13 (72) 7 (58) 25 (69)
Female 1 (17%) 4 (80%) 5 (28) 5 (42) 11 (31)
Stage at diagnosis
Limited 5 (83%) 0 4 (22) 1 (8) 10 (28)
Extensive 1 (17%) 5 (100%) 14 (78) 11 (92) 26 (72)
ECOG PS
0 2 (33%) 3 (60%) 3 (17) 4 (33) 9 (25)
1 4 (67%) 2 (40%) 15 (83) 8 (67) 27 (75)
Presence of brain mets
Yes 0 1 (20%) 2 (11) 3 (25) 4 (11)
No 6 (100%) 4 (80%) 16 (89) 9 (75) 32 (89)
Prior therapy
Platinum-based chemo 6 (100%) 5 (100%) 18 (100) 12 (100) 36 (100)
Chest radiation 6 (100%) 3 (60%) 10 (56) 5 (42) 21 (58)
PCI 3 (50%) 1 (20%) 6 (33) 0 9 (25)
Response to prior therapy
Sensitive relapsed 18 (100) 0
Refractory 0 12 (100)
ECOG PS, Eastern Cooperative Oncology Group performance status; PCI, prophylactic cranial irradiation.
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relapsed cohort had prolonged response on treatment, with
one patient progressing after 19 cycles and another coming
off study after 30 cycles for ileus, rather than disease pro-
gression.
DISCUSSION
Multiple bcl-2 family inhibitors have been under inves-
tigation for their importance in the pathogenesis and response
to treatment in SCLC.16–21 The goal of this phase I/II study
was to evaluate the safety of combining AT-101 with topo-
tecan in the second-line treatment of SCLC and to assess for
evidence of efficacy that would warrant moving forward in
future trials (Table 3).
A total of 11 patients were treated in the phase I portion
of the study. Because of the evidence from other studies that
escalating the AT-101 dose to 60 mg/d led to dose-limiting
FIGURE 1. Waterfall plot of response in all patients.
TABLE 2. Adverse Events Observed in at Least 10% of Patients
System Adverse Event
Grade 1,
n (%)
Grade 2,
n (%)
Grade 3,
n (%)
Grade 4,
n (%)
Grade 5,
n (%)
All,
n (%)
Blood/lymphatic Anemia 2 (5.6) 11 (30.6) 8 (22.2) 2 (5.6) 0 23 (63.9)
Neutropenia 0 3 (8.3) 5 (13.9) 11 (30.6) 0 19 (52.8)
Thrombocytopenia 0 1 (2.8) 5 (13.9) 10 (27.8) 0 16 (44.4)
Leukopenia 1 (2.8) 0 7 (19.4) 5 (13.9) 0 13 (36.1)
Gastrointestinal Nausea 12 (33.3) 2 (5.6) 1 (2.8) 0 0 15 (41.7)
Vomiting 6 (16.7) 2 (5.6) 0 0 0 8 (22.2)
Diarrhea 5 (13.9) 2 (5.6) 0 0 0 7 (19.4)
Abdominal pain upper 4 (11.1) 2 (5.6) 0 0 0 6 (16.7)
Constipation 3 (8.3) 2 (5.6) 1 (2.8) 0 0 6 (16.7)
General disorders Fatigue 2 (5.6) 12 (33.3) 2 (5.6) 0 0 16 (44.4)
Gait disturbance 2 (5.6) 2 (5.6) 0 0 0 4 (11.1)
Metabolism and nutrition Anorexia, decreased appetite
or decreased weight
8 (22.2) 1 (2.8) 1 (2.8) 0 0 10 (27.8)
Dehydration 1 (2.8) 2 (5.6) 1 (2.8) 0 0 4 (11.1)
Hyponatremia 0 0 3 (8.3) 1 (2.8) 0 4 (11.1)
Infections Nasopharyngitis 2 (5.6) 2 (5.6) 0 0 0 4 (11.1)
Pneumonia 1 (2.8) 0 2 (5.6) 1 (2.8) 0 4 (11.1)
Respiratory Dyspnea 2 (5.6) 4 (11.1) 3 (8.3) 0 0 9 (25)
Nervous system disorder Dizziness 3 (8.3) 0 1 (2.8) 0 0 4 (11.1)
Headache 4 (11.1) 0 0 0 0 4 (11.1)
Skin and subcutaneous
tissue disorders
Alopecia 2 (5.6) 2 (5.6) 0 0 0 4 (11.1)
One patient experienced grade 3 elevation in lactate dehydrogenase, and one patient experienced grade 3 elevation in gamma-glutamyl
transferase. Combined, the liver enzyme abnormalities occurred in two patients (5.6%).
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FIGURE 2. Waterfall plot of response at the RP2D dose/cohort A—sensitive relapsed.
FIGURE 3. Waterfall plot of response at the RP2D dose/cohort B—refractory.
TABLE 3. Efficacy Endpoints
Cohort A (n  18) at RP2D Cohort B (n  12) at RP2D All Patients (n  36)
n (%) 95% CI n (%) 95% CI n (%) 95% CI
CR 0 0.0–18.5 0 0.0–26.5 0 0.0–9.7
PR 3 (16.7) 3.6–18.5 0 0.0–26.5 4 (11.1) 3.1–26.1
SD 10 (55.6) 30.8–41.4 5 (41.7) 15.2–72.3 20 (55.6) 38.1–72.1
PD 4 (22.2) 6.4–47.6 5 (41.7) 15.2–72.3 9 (25.0) 12.1–42.2
Unknown 1 (5.6) 0.1–27.3 2 (16.7) 2.1–48.4 3 (8.3) 1.8–22.5
TTP
Median (range)
weeks
17.4 (5.3–36.1) 11.6–24.6 11.7 (1.9–19.4) 7.6–14.1
CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; TTP, time
to progression.
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elevation in liver enzymes, it was determined that dose
escalation above 40 mg/d should not occur. Because two
patients at the 40 mg dose experienced DLTs of grade 4
neutropenia 7 days, a dose deescalation to AT-101 at 30
mg/d was tested. Although no DLTs were observed at this
level, there were several hematologic toxicities including
grade 4 neutropenia lasting7 days in two patients and grade
4 thrombocytopenia lasting 7 days in one patient. Because
AT-101 is given in combination with topotecan, which is
known to have high rates of hematologic toxicities, the
investigator team determined on reviewing the DLT data that
these changes at both the AT-101 doses were consistent with
what could be expected from topotecan alone. In addition,
contrary to other studies, which showed DLTs of gastroin-
testinal complications such as ileus or small bowel obstruc-
tion, these were not found in either of the doses studied.
Given this, it was determined that the recommended phase II
dose was 40 mg/d of AT-101 in combination with topotecan,
and the use of growth factors was recommended. An alter-
native approach to separating out the hematologic toxicities
of topotecan would have been to test single-agent AT-101
alone in the refractory population; this would have given a
clearer picture of the hematologic toxicities specific to AT-
101. However, in this study, we chose to treat all patients
with a combination of topotecan and AT-101. Single-agent
AT-101 was studied in a phase II trial in refractory SCLC,
which was run concurrently; in this trial, only 1 of 14
patients had grade 3 leukopenia, which was not deemed to
be related to treatment.22
In terms of efficacy, this study did not meet its pre-
specified criteria to continue enrollment into the second
stages of the phase II portion of the study, in either the
sensitive-relapsed or refractory cohorts. Interestingly, the
waterfall plot in the sensitive-relapsed cohort (Figure 2)
shows that many patients did have some shrinkage of disease,
although not meeting criteria for PR. Notably, two patients
who had PR had a prolonged response on therapy, suggesting
that in some patients, there may be prolonged benefit that can
be seen. Although the prespecified endpoint for efficacy was
not achieved, these data suggest that this combination may
have some efficacy, particularly in the sensitive-relapsed
population.
No biomarker analysis was conducted in this pilot trial,
and no blood or tumor samples were required for study entry.
Particularly, in the patients who had prolonged response to
therapy, such analysis would have been helpful to try to
identify subpopulations that may specifically benefit from this
combination. This is particularly relevant because studies are
ongoing of AT-101 in first-line SCLC and in the refractory
setting. In addition, multiple other bcl-2 inhibitors are under
investigation in SCLC, and assessing whether these inhibitors
are hitting the relevant targets will be vitally important in
better understanding the success or failure of these drugs.
Oblimersen, an antisense oligonucleotide agent targeting
bcl-2 mRNA, was tested extensively in SCLC,23,24 but a
randomized phase II study in first-line treatment showed
no benefit when added to carboplatin and etoposide.25
Interestingly, repetitive peripheral blood mononuclear cell
sampling of patients receiving oblimersen in a phase I
study did not show significant change in bcl-2 protein
levels.24 Other bcl-2 inhibitors, including small molecule
BH3 mimetics such as obatoclax (GX15–070)26,27 and
AT-26328 are still under study.
There are several possible explanations for the negative
results of this trial. Perhaps bcl-2, although overexpressed in
SCLC, is not an important therapeutic target. However, many
in vitro and in vivo studies have correlated increased bcl-2
expression with tumor invasion and metastasis and chemore-
sistance, and inhibition of bcl-2 has been shown to be asso-
ciated with SCLC regression, suggesting that bcl-2 is indeed
a valid target in SCLC.29–31 Alternatively, it is possible that
the drug was not hitting its target. Biomarker analysis to
assess on-target effects would have been helpful to better
assess this and should be incorporated into future studies.
Finally, it may be that similar to other targeted agents, the
majority of the benefit with this drug may reside in a specific
subset of patients, molecularly defined, that has not been fully
elucidated yet. Again, tumor tissue analysis and assessment
of on-target effects would be helpful to better define this.
In summary, the bcl-2 family inhibitor AT-101 given
40 mg, days 1 to 5 could be safely combined with topotecan
at a reduced dose of 1.25 mg/m2 days 1 to 5 in the treatment
of SCLC. The study did not meet its prespecified endpoints
for continuation of enrollment and was stopped in both the
sensitive-relapsed and refractory cohorts after the first stage
of the two-stage phase II design. Intriguingly, long PFS and
prolonged responses in two patients suggest that inhibition of
this pathway may be a reasonable strategy, particularly in a
subset of patients who have yet to be fully defined.
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